Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.22
-0.05 (-0.17%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 20, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 19, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Swixx BioPharma Consolidates QMS, RIM, and Safety Processes Digital with the CARA Life Sciences Platform
January 11, 2024
LONDON - Jan. 11, 2024 - PRLog -- Generis, creator of the cloud data, content, and business process management platform CARA™, announces that Swixx BioPharma has selected the CARA Life Sciences...
Via
PRLog
Generis and Userlane Forge Strategic Partnership to Accelerate Digital Transformation in Regulated Industries
December 19, 2023
LONDON - Dec. 19, 2023 - PRLog -- Generis and Userlane today announced a strategic partnership. Generis is the developer of the CARA platform for data, content, and business process management in...
Via
PRLog
UnitedHealth's rising premiums could cushion stubborn inflation
January 17, 2024
The healthcare sector is one of the prime suspects to attract safety-seeking investors in the coming market shift. Within it, THIS stock can prove a winner
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
January 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
DGE’s 3rd Real World Evidence & Market Access
January 11, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
December 15, 2023
Via
Investor Brand Network
Exposures
COVID-19
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Via
MarketBeat
Exposures
COVID-19
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
January 10, 2024
From
Pfizer Inc.
Via
Business Wire
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Genmab A/S
Via
Business Wire
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Pfizer Inc.
Via
Business Wire
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
January 08, 2024
From
Pfizer Inc.
Via
Business Wire
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Is the January Effect reliable indicator for yearly performance?
January 04, 2024
The January Effect refers to January’s market return as predictive of the full year. But is January's performance truly an indicator of how the year may go?
Via
MarketBeat
Topics
ETFs
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 02, 2024
From
Pfizer Inc.
Via
Business Wire
Align Technology: Protected by more factors than any other stock
December 26, 2023
Jobs are flowing to the healthcare space, and investment dollars are finding a home in stocks like Align Technology, even the CEO thought it to be the best
Via
MarketBeat
Pfizer's chaotic year wraps up with plunging stock, grim guidance
December 21, 2023
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets.
Via
MarketBeat
Exposures
COVID-19
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
December 19, 2023
From
Pfizer Inc.
Via
Business Wire
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
December 15, 2023
From
Pfizer Inc.
Via
Business Wire
Texas Has Given Birth to Its First and Only Global Publicly Traded Cannabis Company, Cannabis Bioscience International Holdings
December 15, 2023
Houston, Texas--(Newsfile Corp. - December 15, 2023) - On December 5, 2023, Cannabis Bioscience International Holdings (OTC Pink: CBIH) ,...
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
Quick list of bargain stocks to end the year
December 15, 2023
Stocks are soaring after a FED dovish pivot, making these value stocks all the more attractive today. Analysts have built up cases as to why they will rally
Via
MarketBeat
Pfizer Declares First-Quarter 2024 Dividend
December 14, 2023
From
Pfizer Inc.
Via
Business Wire
The Vaccine Group appoints advisory board in partnering push
December 14, 2023
Frontier IP Group PLC (AIM:FIPP, OTC:FGPPF) portfolio company The Vaccine Group (TVG) CEO Jeremy Salt speaks to Proactive after announcing that TVG has established an advisory board comprised of what...
Via
TheNewswire.com
Topics
Retirement
Exposures
Pension
Pfizer Completes Acquisition of Seagen
December 14, 2023
From
Pfizer Inc.
Via
Business Wire
Can Altimmune's weight-loss drug be a game-changer?
December 14, 2023
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.